Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antidepressant norepinephrine reuptake inhibitor |
| gptkbp:approvedBy |
gptkb:Europe
1997 |
| gptkbp:ATCCode |
N06AX18
|
| gptkbp:brand |
gptkb:Edronax
gptkb:Vestra Norebox |
| gptkbp:CASNumber |
98769-81-4
|
| gptkbp:compatibleWith |
gptkb:United_States
|
| gptkbp:developedBy |
gptkb:Pfizer
|
| gptkbp:eliminationHalfLife |
13 hours
|
| gptkbp:hasMolecularFormula |
C19H23NO3
|
| https://www.w3.org/2000/01/rdf-schema#label |
Reboxetine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
selective norepinephrine reuptake inhibition
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
gptkb:C_(Australia)
|
| gptkbp:proteinBinding |
97%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
constipation
increased heart rate sweating insomnia dry mouth |
| gptkbp:synonym |
(R,R)-2-[(α-(2-ethoxyphenoxy)benzyl)morpholine]
|
| gptkbp:usedFor |
gptkb:major_depressive_disorder
|
| gptkbp:bfsParent |
gptkb:Antidepressants
|
| gptkbp:bfsLayer |
6
|